{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:09:32Z","timestamp":1772708972622,"version":"3.50.1"},"reference-count":126,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Cardiovascular Therapy"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1586\/14779072.2013.844546","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T05:50:42Z","timestamp":1384235442000},"page":"1597-1612","source":"Crossref","is-referenced-by-count":2,"title":["Searching the place of pitavastatin in the current treatment of patients with dyslipidemia"],"prefix":"10.1586","volume":"11","author":[{"given":"Vivencio","family":"Barrios","sequence":"first","affiliation":[{"name":"Cardiology department","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[{"name":"Cardiology department","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L","family":"Zamorano","sequence":"additional","affiliation":[{"name":"Cardiology department","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2010.11.005"},{"issue":"8","key":"e_1_3_3_8_1","first-page":"395","article-title":"Clinical profile of a hypercholesterolemic Spanish population and differences between genders. LIPYCARE study","volume":"21","author":"Barrios V","year":"2004","unstructured":"Barrios V, Martinez M, Tomas JP et al. Clinical profile of a hypercholesterolemic Spanish population and differences between genders. LIPYCARE study. Hipertensi\u00f3n 21(8), 395\u2013402 (2004).","journal-title":"Hipertensi\u00f3n"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2007.06481.x"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1157\/13126342"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.05.033"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.580"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S011"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.082"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60330-5"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1157\/13072841"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr080"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s2048"},{"key":"e_1_3_3_20_1","unstructured":"LIVALO [prescribing information]. Kowa Pharmaceuticals America Inc Montgomery AL (2012)."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5688(10)71063-1"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.07.011"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003641990"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/clp.10.28"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S5551"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622310389227"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1554-0"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0075-4"},{"issue":"3","key":"e_1_3_3_29_1","first-page":"577","article-title":"Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males","volume":"26","author":"Zhu J","year":"2013","unstructured":"Zhu J, Song M, Tan HY et al. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males. Pak. J. Pharm. Sci. 26(3), 577\u2013584 (2013).","journal-title":"Pak. J. Pharm. Sci"},{"issue":"3","key":"e_1_3_3_30_1","first-page":"187","article-title":"CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics","volume":"68","author":"Zhou Q","year":"2013","unstructured":"Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, Zeng S. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie 68(3), 187\u2013194 (2013).","journal-title":"Pharmazie"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-12-RG-067"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318251addb"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.01.026"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.648264"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016112799305021"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.589433"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010379811"},{"issue":"3","key":"e_1_3_3_38_1","first-page":"323","article-title":"Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics","volume":"11","author":"Neuvonen PJ","year":"2010","unstructured":"Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin Investig. Drugs 11(3), 323\u2013332 (2010).","journal-title":"Curr. Opin Investig. Drugs"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.068536"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/11592480-000000000-00000"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e318256cdf0"},{"issue":"4","key":"e_1_3_3_43_1","first-page":"251","article-title":"Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison","volume":"52","author":"Saito Y","year":"2002","unstructured":"Saito Y, Yamada N, Teramoto T et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52(4), 251\u2013255 (2002).","journal-title":"Arzneimittelforschung"},{"issue":"14","key":"e_1_3_3_44_1","first-page":"968","article-title":"Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study","volume":"92","author":"Mao Y","year":"2012","unstructured":"Mao Y, Yu JM, Zhan YQ et al. Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study. Zhonghua. Yi. Xue. Za. Zhi. 92(14), 968\u2013973 (2012).","journal-title":"Zhonghua. Yi. Xue. Za. Zhi"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.007"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903290886"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0056-7"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00712-2"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.11.002"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.02.008"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.2217\/clp.09.20"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M522"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01274.x"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-1281"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.12.009"},{"issue":"8","key":"e_1_3_3_56_1","first-page":"709","article-title":"A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO\u00ae Tablet)-LIVALO Effectiveness and safety (LIVES) Study","volume":"36","author":"Kurihara Y","year":"2008","unstructured":"Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO\u00ae Tablet)-LIVALO Effectiveness and safety (LIVES) Study. Jpn Pharmacol. Ther. 36(8), 709\u2013731 (2008).","journal-title":"Jpn Pharmacol. Ther"},{"issue":"9","key":"e_1_3_3_57_1","first-page":"789","article-title":"A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia: LIVES 5-year extension study","volume":"39","author":"Teramoto T","year":"2011","unstructured":"Teramoto T, Urashima M, Shimano H et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia: LIVES 5-year extension study. Jpn. Pharmacol. Ther. 39(9), 789\u2013803 (2011).","journal-title":"Jpn. Pharmacol. Ther"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.1719"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5688(11)70888-1"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1586\/erc.11.47"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5688(10)71064-3"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.660525"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.017"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0057-6"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871525711311020007"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.000071"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S13492"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.13.123"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.12.2980-a"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.E1008"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.E562"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01477.x"},{"issue":"7","key":"e_1_3_3_74_1","first-page":"508","article-title":"The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia","volume":"51","author":"Mao Y","year":"2012","unstructured":"Mao Y, Yu JM, Zhang F et al. The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia. Zhonghua. Nei. Ke. Za. Zhi. 51(7), 508\u2013512 (2012).","journal-title":"Zhonghua. Nei. Ke. Za. Zhi"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03240.x"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2005.03.004"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.025"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.12.031"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.3764"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-012-0689-0"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01566.x"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.01.054"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1159\/000091956"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2728"},{"issue":"5","key":"e_1_3_3_85_1","first-page":"683","article-title":"Differential effect of statins on diabetic nephropathy in db\/db mice","volume":"28","author":"Tamura Y","year":"2011","unstructured":"Tamura Y, Murayama T, Minami M, Yokode M, Arai H. Differential effect of statins on diabetic nephropathy in db\/db mice. Int. J. Mol. Med. 28(5), 683\u2013687 (2011).","journal-title":"Int. J. Mol. Med"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04139.x"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591190-000000000-00000"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-8-201004200-00005"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487312451251"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487312437326"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110874"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-08-1051"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.033"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.5660"},{"issue":"2","key":"e_1_3_3_96_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.atherosclerosis.2011.08.024","article-title":"Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial","volume":"219","author":"Hibi K","year":"2011","unstructured":"Hibi K, Kimura T, Kimura K et al.; JAPAN-ACS Investigators. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis 219(2), 743\u2013749 (2011).","journal-title":"Atherosclerosis"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2012.04.003"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-1163"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-1356"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.07.009"},{"issue":"6","key":"e_1_3_3_101_1","first-page":"385","article-title":"Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage","volume":"4","author":"Ibuki C","year":"2012","unstructured":"Ibuki C, Seino Y, Otsuka T et al. Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage. J. Clin. Med. Res. 4(6), 385\u2013392 (2012).","journal-title":"J. Clin. Med. Res"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.13862"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.E581"},{"issue":"24","key":"e_1_3_3_104_1","first-page":"1681","article-title":"Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis","volume":"92","author":"Mao Y","year":"2012","unstructured":"Mao Y, Yu JM, Zhan YQ et al. Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis. Zhonghua. Yi Xue. Za. Zhi. 92(24), 1681\u20131685 (2012).","journal-title":"Zhonghua. Yi Xue. Za. Zhi"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2012.07.012"},{"issue":"5","key":"e_1_3_3_106_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIRCOUTCOMES.110.938118","article-title":"Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for \u201cintermediate risk\u201d","volume":"3","author":"Ridker PM","year":"2010","unstructured":"Ridker PM, Macfadyen JG, Nordestgaard BG et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for \u201cintermediate risk\u201d. Circ. Cardiovasc. Qual. Outcomes 3(5), 447\u2013452 (2010).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2013.03.008"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S31346"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.3109\/15376516.2011.603391"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.10.069"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.17210"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.01.040"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.583238"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S44099"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.5"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.72.538"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e318165dcad"},{"key":"e_1_3_3_118_1","article-title":"Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study)","author":"Ikeda K","year":"2012","unstructured":"Ikeda K, Takahashi T, Yamada H et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). Eur. J. Prev. Cardiol. doi:10.1177\/2047487312451539 (2012) (Epub ahead of print).","journal-title":"Eur. J. Prev. Cardiol"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2008.08.011"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-013-6464-y"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0722"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.01.009"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.01082.x"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00769.x"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23464"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1179\/1743132812Y.0000000127"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.06.011"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1179\/1743132812Y.0000000054"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.07.006"},{"key":"e_1_3_4_2_1","unstructured":"Pitavastatin. Public Assessment Report. Medicines and Healthcare Products Regulatory Agency. www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con096843.pdf"}],"container-title":["Expert Review of Cardiovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14779072.2013.844546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:20:50Z","timestamp":1772706050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14779072.2013.844546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":126,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1586\/14779072.2013.844546"],"URL":"https:\/\/doi.org\/10.1586\/14779072.2013.844546","relation":{},"ISSN":["1477-9072","1744-8344"],"issn-type":[{"value":"1477-9072","type":"print"},{"value":"1744-8344","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}